Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01864356 · ClinicalTrials.gov registry record · Phase 2
A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)
A Phase 2 study of Repeated IVF Failure, sponsored by Nora Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
- 20
- Study locations
NCT01864356: Completed Phase 2 study of Repeated IVF Failure, sponsored by Nora Therapeutics.
NCT01864356 is a Phase 2 study of Repeated IVF Failure that has completed, run by Nora Therapeutics. The registered enrollment target is 157 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01864356, a Phase 2 study of Repeated IVF Failure, has completed, sponsored by Nora Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of subcutaneous NT100 vs placebo following in vitro fertilization (IVF) in women with a history of repeated IVF failures.
Primary Outcome
The primary efficacy outcome measure is the ongoing clinical pregnancy rate at Week 8 of gestation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NT100
Study Locations (20)
California
- HRC Fertility - Encino
- HRC Fertility - Newport Beach
- HRC Fertility - Pasadena
- UCSF - San Francisco
Texas
- Center for Assisted Reproduction - Bedford
- Houston Fertility Institute - Houston
- Center of Reproductive Medicine - Webster
Florida
- Florida Fertility Institute - Clearwater
- IVF and Fertility Center of Miami - Miami
Illinois
- Fertility Centers of Illinois / River North IVF Center - Chicago
- Fertility Centers of Illinois / Highland Park IVF Center - Highland Park
Massachusetts
- Brigham and Women's Hospital - Boston
- Boston IVF - Waltham
Delaware
- Reproductive Associates of Delaware - Newark
District of Columbia
- Columbia Fertility Associates - Washington D.C.
Georgia
- Georgia Reproductive Specialists - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
What the finished NCT01864356 record still lists
NCT01864356 is an interventional study that assigns participants to a tested intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% higher).
The record links to 1 condition, with Repeated IVF Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01864356 names 20 study sites across 12 states, led by California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT01864356 about?
NCT01864356 is a clinical study titled "A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)". The purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of subcutaneous NT100 vs placebo following in vitro fertilization (IVF) in women with a history of repeated IVF failures.
What is the current status of trial NCT01864356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2013-05. Estimated completion is 2014-09.
What conditions does trial NCT01864356 study?
This clinical trial studies the following conditions: Repeated IVF Failure.
What interventions are being tested in trial NCT01864356?
The interventions under investigation include: Placebo (DRUG), NT100 (DRUG).
Who is sponsoring clinical trial NCT01864356?
This trial is sponsored by Nora Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01864356 being conducted?
This trial has 20 study locations across California, Delaware, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01864356's enrollment target sits among peer trials
157 443rd of 2000 higher than 1,556 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05052541 · 157 participants · Phase 3
Safety and Efficacy of Oral Cannabis in Chronic Spine Pain
- NCT05076942 · 157 participants · Phase 2
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
- NCT06396598 · 157 participants · NA
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
- NCT06655246 · 157 participants · Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia